DexEnceph — Adjunct Dexamethasone in HSV Encephalitis

1. Publication

• Title: Safety and efficacy of adjunct dexamethasone in adults with herpes simplex virus encephalitis in the UK
• Acronym: DexEnceph
• Year & Journal: The Lancet Neurology, 2026;25(2):136-146 (published January 21, 2026; correction January 29, 2026)
• Citation: Solomon T, Hooper C, Easton A, et al; DexEnceph Study Group. Safety and efficacy of adjunct dexamethasone in adults with herpes simplex virus encephalitis in the UK (DexEnceph): a multicentre, observer-blind, randomised, phase 3, controlled trial. Lancet Neurol. 2026;25(2):136-146. doi:10.1016/S1474-4422(25)00454-5

2. Context & Rationale

Background: HSV encephalitis is the most common sporadic viral encephalitis worldwide. Aciclovir transformed survival since the 1970s, but many survivors are left with long-term cognitive difficulties, especially memory problems. Corticosteroids are already used in other inflammatory brain diseases (e.g., autoimmune encephalitis), and clinicians increasingly want to give corticosteroids early when encephalitis of uncertain cause is suspected — but until HSV encephalitis was ruled out, this was not felt to be safe, given theoretical concern that immunosuppression could worsen viral replication.

Research Question/Hypothesis: In adults with HSV encephalitis, does adjunct dexamethasone (added to standard aciclovir) improve verbal memory outcome at 26 weeks compared with aciclovir alone, and is it safe (i.e., does it not worsen viral replication/outcomes)?

Why This Matters: This is described as the first completed RCT of corticosteroid therapy in HSV encephalitis, directly addressing a decades-old clinical uncertainty and a specific safety question relevant to the common real-world scenario of empirically treating suspected encephalitis of uncertain cause.

3. Design & Methods

• Study Type: Pragmatic, multicenter, randomized, controlled, observer-blind, phase 3 trial
• Setting & Centers: 53 NHS hospitals, UK; recruited September 22, 2016 – February 2, 2022
• Population:
• Inclusion: Adults ≥16y with suspected encephalitis (febrile illness with new-onset seizure, new focal neurological signs, or altered consciousness/cognition/personality/behavior) and positive HSV type 1 or 2 PCR in CSF
• Exclusions: Not further detailed in available trial text
• Intervention: IV dexamethasone 10 mg four times daily for 4 days, plus IV aciclovir 10 mg/kg three times daily for ≥14 days
• Comparator: IV aciclovir alone (same regimen)
• Blinding: Observer-blind (outcome assessors blinded; treatment delivery not blinded to clinical team, per the pragmatic open-label drug administration)
• Statistical Power & Follow-Up: Target 90 patients (recruited 94: 47/47). Primary outcome: verbal memory score (Wechsler Memory Scale [WMS]-IV Auditory Memory Index) at 26 weeks. Patients who died were assigned the lowest possible WMS-IV score (a prespecified handling of mortality within the primary outcome). Secondary outcomes to 78 weeks including additional neuropsychological, clinical, functional, and neuroimaging measures. Safety monitoring included CSF HSV DNA at 2 weeks post-randomization (surveillance for enhanced viral replication).

4. Key Results

94 participants recruited (47 dexamethasone+aciclovir, 47 aciclovir alone).

Note on data completeness: Exact numeric primary-outcome values (mean WMS-IV scores and between-group difference with CI) were not available in the accessible source text used for this summary; the qualitative primary conclusion ("no big difference") and the safety/timing findings above are accurately reported per available sources, but readers should consult the primary Lancet Neurology publication directly for the precise primary-outcome statistics.

5. Internal Validity Assessment

• Randomization & Allocation: Secure web-based randomization system used for allocation; specific concealment details beyond this not fully available in accessible text.
• Protocol Adherence & Separation: Protocolized dosing (dexamethasone 10mg QID ×4 days; note a correction was published regarding this dose being stated incorrectly in the original manuscript's Summary/Methods/Research-in-Context panel) alongside standard aciclovir in both arms.
• Blinding & Detection Bias: Observer-blind design (outcome assessors blinded) reduces detection bias for the neuropsychological primary outcome, though treatment delivery itself was open (pragmatic design).
• Missing Data & Sensitivity Analyses: Patients who died were assigned the lowest possible WMS-IV score by prespecified convention — a sound method for handling mortality within a continuous cognitive-outcome primary endpoint, avoiding survivor-bias distortion.
• Overall Internal Validity Conclusion: Moderate — observer-blind design and a sound death-handling convention are strengths; however, this was a modestly sized trial (94 patients, recruited over nearly 6 years, below some earlier target sizes referenced in trial protocol documents) for a rare disease, limiting statistical power for smaller effect sizes.

6. External Validity Assessment

• Population Representativeness: UK-wide, 53-hospital NHS trial in PCR-confirmed HSV encephalitis — the largest RCT of its kind in this specific, rare, severe condition.
• Practice Context: Requires CSF PCR confirmation of HSV before/around the treatment decision — standard of care in most high-resource health systems managing suspected encephalitis.
• Overall External Validity Conclusion: Good for high-resource health systems with CSF PCR diagnostic capability managing confirmed HSV encephalitis; this being the first completed RCT of corticosteroids in this disease means there is no directly comparable prior trial evidence to weigh against it.

7. Strengths & Limitations

Strengths:

• First completed RCT of corticosteroid therapy in HSV encephalitis, addressing a decades-old clinical uncertainty
• Directly tests (and resolves, at least for this trial) a specific, clinically important safety concern (enhanced viral replication) via CSF HSV DNA surveillance
• Observer-blind design with a sound, prespecified method for handling mortality within the primary cognitive outcome
• Long follow-up (to 78 weeks) capturing a range of neuropsychological, functional, and imaging outcomes beyond the primary endpoint

Limitations:

• Modest sample size (94 patients) for a trial that took nearly 6 years to recruit, given the rarity of the condition
• No significant primary-outcome benefit, limiting the trial's ability to change practice toward routine dexamethasone use
• The timing-of-treatment signal (earlier dexamethasone → better memory scores) is exploratory/hypothesis-generating, not a confirmed causal finding
• Precise primary-outcome effect-size statistics were not fully accessible for this summary

8. Interpretation & Practice Impact

• Clinical Implications: Dexamethasone did not improve verbal memory outcomes when added to aciclovir for HSV encephalitis, but importantly, it was also shown to be safe — no evidence of enhanced viral replication or worse outcomes. This safety finding is itself clinically significant: it suggests dexamethasone could reasonably be considered early in suspected encephalitis of uncertain cause (e.g., possible autoimmune encephalitis), before HSV has been definitively ruled out, without the previously-feared risk of worsening a missed HSV case.
• Mechanistic Coherence: The absence of enhanced viral replication is consistent with dexamethasone's short (4-day), targeted dosing course alongside effective concurrent antiviral therapy.
• Systems-Level Takeaway: Removes a specific barrier (fear of harm) to earlier empiric corticosteroid use in suspected encephalitis of uncertain etiology, even though it does not establish a positive indication for dexamethasone specifically in confirmed HSV encephalitis.

9. Controversies & Subsequent Evidence

• Editorial Commentary/Debates: Chief investigator Tom Solomon has publicly framed the central, decades-long clinical dilemma this trial addresses: whether corticosteroids would improve HSV encephalitis outcomes or worsen them via immunosuppression — the trial's clearest contribution is resolving the safety half of that question, even without establishing efficacy.
• Guideline Integration: Described by the University of Liverpool (institutional press release) as providing "definitive evidence" specifically on safety; the exploratory early-treatment-timing signal is noted as an area for potential future research rather than an established guideline-changing finding.

10. Summary & Executive Takeaway

Summary: DexEnceph, the first completed RCT of corticosteroids in HSV encephalitis, randomized 94 adults across 53 UK hospitals to adjunct dexamethasone or aciclovir alone. There was no significant difference in the primary outcome (verbal memory at 26 weeks), but dexamethasone was shown to be safe, with no evidence of enhanced viral replication. An exploratory signal suggested earlier dexamethasone initiation was associated with better memory scores.

Overall Takeaway: Adjunct dexamethasone does not improve verbal memory outcomes in HSV encephalitis, but its demonstrated safety removes a longstanding barrier to earlier empiric corticosteroid use in suspected encephalitis of uncertain cause — a meaningful, if not efficacy-establishing, practice-relevant result from the first trial of its kind.

11. Bibliography

• Whitfield T, et al. Protocol for DexEnceph: a randomised controlled trial of dexamethasone therapy in adults with herpes simplex virus encephalitis. BMJ Open. 2021;11(7):e041808.